相似文献
1
Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients.
Ann Neurol. 2024 Sep;96(3):453-459. doi: 10.1002/ana.27027. Epub 2024 Jul 4.
2
Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Cochrane Database Syst Rev. 2014 Jun 10;2014(6):CD008782. doi: 10.1002/14651858.CD008782.pub4.
3
The impact of kidney function on Alzheimer's disease blood biomarkers: implications for predicting amyloid-β positivity.
Alzheimers Res Ther. 2025 Feb 19;17(1):48. doi: 10.1186/s13195-025-01692-z.
4
Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study.
Lancet Neurol. 2024 Dec;23(12):1214-1224. doi: 10.1016/S1474-4422(24)00426-5.
5
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Cochrane Database Syst Rev. 2017 Mar 22;3(3):CD010803. doi: 10.1002/14651858.CD010803.pub2.
6
Neurofilament light chain and Alzheimer pathology biomarkers in elderly people with multiple sclerosis.
J Neurol Sci. 2025 Aug 15;475:123562. doi: 10.1016/j.jns.2025.123562. Epub 2025 Jun 2.
7
Plasma S100β is a predictor for pathology and cognitive decline in Alzheimer's disease.
Fluids Barriers CNS. 2025 Jan 9;22(1):4. doi: 10.1186/s12987-024-00615-8.
8
Azathioprine for people with multiple sclerosis.
Cochrane Database Syst Rev. 2024 Dec 9;12(12):CD015005. doi: 10.1002/14651858.CD015005.pub2.
9
The AlzMatch Pilot Study - Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer's Disease Trials.
J Prev Alzheimers Dis. 2024;11(5):1435-1444. doi: 10.14283/jpad.2024.101.
10
18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012884. doi: 10.1002/14651858.CD012884.
引用本文的文献
1
Neuropathological Evidence of Reduced Amyloid Beta and Neurofibrillary Tangles in Multiple Sclerosis Cortex.
Ann Neurol. 2025 Jun;97(6):1067-1073. doi: 10.1002/ana.27231. Epub 2025 Apr 8.
2
Senescent brain cell types in Alzheimer's disease: Pathological mechanisms and therapeutic opportunities.
Neurotherapeutics. 2025 Apr;22(3):e00519. doi: 10.1016/j.neurot.2024.e00519. Epub 2025 Jan 6.
3
More than microglia: myeloid cells and biomarkers in neurodegeneration.
Front Neurosci. 2024 Oct 31;18:1499458. doi: 10.3389/fnins.2024.1499458. eCollection 2024.
本文引用的文献
1
Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid.
Alzheimers Dement. 2024 May;20(5):3179-3192. doi: 10.1002/alz.13764. Epub 2024 Mar 16.
2
Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests.
Nat Med. 2024 Apr;30(4):1085-1095. doi: 10.1038/s41591-024-02869-z. Epub 2024 Feb 21.
3
Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease.
Alzheimers Dement. 2024 Feb;20(2):1214-1224. doi: 10.1002/alz.13542. Epub 2023 Nov 6.
4
Etiology, effects and management of comorbidities in multiple sclerosis: recent advances.
Front Immunol. 2023 May 30;14:1197195. doi: 10.3389/fimmu.2023.1197195. eCollection 2023.
5
Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape.
Neuron. 2023 Sep 20;111(18):2781-2799. doi: 10.1016/j.neuron.2023.05.017. Epub 2023 Jun 8.
6
The role of cerebrospinal fluid and other biomarker modalities in the Alzheimer's disease diagnostic revolution.
Nat Aging. 2023 May;3(5):460-462. doi: 10.1038/s43587-023-00400-6.
7
Population-Based Estimates for the Prevalence of Multiple Sclerosis in the United States by Race, Ethnicity, Age, Sex, and Geographic Region.
JAMA Neurol. 2023 Jul 1;80(7):693-701. doi: 10.1001/jamaneurol.2023.1135.
8
Alzheimer Disease.
Continuum (Minneap Minn). 2022 Jun 1;28(3):648-675. doi: 10.1212/CON.0000000000001131.
9
Performance of plasma phosphorylated tau 181 and 217 in the community.
Nat Med. 2022 Jul;28(7):1398-1405. doi: 10.1038/s41591-022-01822-2. Epub 2022 May 26.
10
Quantification of amyloid beta and tau PET without a structural MRI.
Alzheimers Dement. 2023 Feb;19(2):444-455. doi: 10.1002/alz.12668. Epub 2022 Apr 16.
Zotero 插件